Showing results (341-350 of 356) with videos related to
Sort By:
Pageof 36
Archives of Neurology|December 1, 1986
Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosisD L Camenga, K P Johnson, M Alter, et al.The Analyst|October 12, 2023
Method for determining resin cure kinetics with low-frequency Raman spectroscopyRobert V Chimenti, Alexandra M Lehman-Chong, Alyssa M Sepcic, et al.Science (New York, N.Y.)|March 26, 2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansGregory L Beatty, Elena G Chiorean, Matthew P Fishman, et al.American Journal of Therapeutics|March 31, 1999
Effect of montelukast on single-dose theophylline pharmacokineticsK Malmstrom, J Schwartz, T F Reiss, et al.Leukemia Research|June 18, 2014
Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancersJennifer A Westwood, Geoffrey M Matthews, Jake Shortt, et al.The Journal of Antimicrobial Chemotherapy|May 17, 2019
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarateKristina M Brooks, Mustafa E Ibrahim, Jose R Castillo-Mancilla, et al.Human Gene Therapy|February 15, 2001
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trialB Wittig, A Märten, T Dorbic, et al.Cancer Research|October 15, 1996
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumorsA S Lübbe, C Bergemann, H Riess, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.Pageof 36